Paralytic ileus after bilateral intravitreal injection of bevacizumab
Sir, There are few reports of systemic adverse events associated with intravitreal injection of bevacizumab (IVB). Rare systemic events include formed visual hallucinations, [1] erectile dysfunction, [2] and acute decrease in kidney function. [3] We recently experienced a case of paralytic ileus after bilateral IVB, thus herein report the case.
A 47-year-old male patient was screened for diabetic retinopathy. He was admitted to the department of internal medicine with uncontrolled Type 2 diabetes mellitus. The blood sugar test was 496 mg/dL and hemoglobin A1c was 13.6%. At the initial ophthalmic examination, his corrected visual acuity was 20/40 in the right eye and 20/30 in the left eye. The intraocular pressure was 18 mmHg in the right eye and 19 mmHg in the left eye. Slit lamp examination revealed no abnormal findings in anterior segment while the funduscopic examination showed microaneurysms and dot hemorrhages in four quadrants. Fluorescein angiography revealed the neovascularization with leakage of dye in both eyes. The IVB (1.25 mg/0.05 mL) was done in both eyes in the same day with patient's request of prompt treatment. Panretinal photocoagulation was scheduled in both eyes after 2 days; however, the laser photocoagulation could not be done because of patient's severe abdominal pain with vomiting and abdominal distension. In our case, the patient had no history of gastrointestinal disorder. Matsuyama et al. reported that the plasma vascular endothelial growth factor (VEGF) level decreased markedly as early as 1 day after IVB in patients with diabetic retinopathy. [4] Thus, it is possible that systemic side effects can develop after IVB as well as after intravenous bevacizumab. Decreased plasma VEGF resulted in the decreased production of nitric oxide, [5] a known vasodilator. Therefore, decreased VEGF production can cause vasoconstriction and reduce the supply of gastrointestinal blood flow. Moreover, the patient received bilateral IVB, which might cause the higher plasma VEGF level than in the case of unilateral IVB.
In conclusion, we report on a patient with paralytic ileus after bilateral IVB. In spite of very low incidences, the physicians should aware of the gastrointestinal disorders such as paralytic ileus following bilateral IVB.
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Adverse drug reactions due to ophthalmic drugs: Reporting system in India
Sir, All new drugs including those for ophthalmic use are approved by Drugs Controller General (India) of Central Drugs Standard Control Organization (CDSCO) as per the schedule Y of Drugs and Cosmetics (D and C) Act 1940 and Rules 1945 thereunder after reviewing its efficacy and safety in Indian population. Even after the approval of new drug, as per schedule Y of the D and C rules, Periodic Safety Update Reports are required to be submitted to CDSCO every 6 months for the first 2 years and for the subsequent 2 years to be submitted annually. [1] Once the drug is introduced in the market, the responsibility to monitor the adverse drug reactions (ADRs) in larger population becomes the obligation of all prescribers as well as the concerned organization. Only a scant amount of ADRs information is available when a drug is introduced in the clinical practice because the investigational drug is exposed in limited subjects and duration. Therefore, there are possibilities of ADRs to occur when the drug has been used in larger population for prolonged periods.
Therefore, pharmacovigilance, known as the science and activity relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem, came into existence to monitor ADRs till the life period of a drug. [2] In India, Ministry of Health and Family Welfare (MoHFW), Government of India launched a nationwide Pharmacovigilance Programme of India (PvPI) in the year 2010 to monitor the safety of drugs including for the ophthalmic use. Indian Pharmacopoeia Commission under the MoHFW functions as National Coordination Centre (NCC) for PvPI. NCC identified 150 ADRs monitoring centres (AMCs) across the country to report ADRs to NCC. [3, 4] An ADR is response to a drug which is noxious and unintended and which occurs at doses normally used in human for the prophylaxis, diagnosis or treatment of disease, or for the modification of physiological function can be reported to AMC-PvPI. A trained team at AMC collects manages and assesses the report before submitting to NCC. A ADRs reporter (healthcare professionals) who is not a part of AMC can report ADRs with all ophthalmic products whether known or unknown, serious or nonserious, and frequent or rare by filling the suspected ADR reporting form [ Fig. 1 ] and submitted in nearby AMC (available in www.ipc. gov.in). A helpline (1800 180 3024) also is available to provide assistance in ADRs reporting. [3] The obtained information is entered in the database, analyzed, and assessed to identify new signals. This is also used as main source for identifying and reducing the risks associated with the ophthalmic drugs.
Submission of ADRs report does not have any legal implication on the reporter and reporter details are maintained confidentially. [5] The provided information used to take regulatory
